Koers Regenicin, Inc. Other OTC
Aandelen
RGIN
US75887Q1022
Biotechnologie & Medisch Onderzoek
Omzet 2021 | - | Omzet 2022 | - | Marktkapitalisatie | 491K 452K |
---|---|---|---|---|---|
Nettowinst (verlies) 2021 | - 0 | Nettowinst (verlies) 2022 | - 0 | EV/omzet 2021 | - |
Nettoschuld 2021 | 598K 551K | Nettoschuld 2022 | 627K 577K | EV/omzet 2022 | - |
K/w-verhouding 2021 |
-2
x | K/w-verhouding 2022 |
-0,71
x | Werknemers | - |
Dividendrendement 2021 * |
-
| Dividendrendement 2022 |
-
| Vrij verhandelbaar | 79,1% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Randall McCoy
CEO | Chief Executive Officer | 74 | 15-07-10 |
John Weber
DFI | Director of Finance/CFO | 74 | 13-09-10 |
J. Nelson
CTO | Chief Tech/Sci/R&D Officer | 75 | 15-07-10 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
John Weber
DFI | Director of Finance/CFO | 74 | 13-09-10 |
Randall McCoy
CEO | Chief Executive Officer | 74 | 15-07-10 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+9,42% | 115 mld. | |
+11,84% | 106 mld. | |
-1,05% | 21,96 mld. | |
-14,15% | 21,87 mld. | |
-5,29% | 19,21 mld. | |
-4,16% | 18,08 mld. | |
-38,29% | 17,71 mld. | |
+7,99% | 14,32 mld. | |
+36,24% | 12,42 mld. |